Back to Journals » Therapeutics and Clinical Risk Management » Volume 2 » Issue 3

An assessment of the cost-utility of therapy for psoriasis

Authors Stefan C Weiss, Wingfield Rehmus, Alexa B Kimball

Published 15 September 2006 Volume 2006:2(3) Pages 325—328

Stefan C Weiss1, Wingfield Rehmus2, Alexa B Kimball3


1Department of Dermatology, Kaiser Permanente Medical Center, Stockton, CA, USA; 2Department of Dermatology, Stanford University, Palo Alto, CA, USA; 3Department of Dermatology, Harvard University, Boston, MA, USA


Objective: Recently a number of new therapies have been introduced to treat psoriasis, but concerns have been expressed about their high cost. The purpose of this study was to determine whether most psoriasis treatments lie within the accepted range of cost-utility.

Methodology: 32 patients with moderate to severe psoriasis were administered the Euro-Qol 5 Dimension (EQ-5D) survey to calculate their health state utility. Economic modeling was performed with a range of therapeutic costs applying the calculated utility score. Paired t-tests were used to calculate significance.

Results: At the conclusion of 2 weeks of therapy, the mean psoriasis area and severity index (PASI) improved 35% to 7.2 (p<0.001). The mean health state utility score on the EQ-5D improved 11.5% from 77.7 units before therapy to 86.7 units after therapy (p=0.007).

Conclusion: A therapy that achieves at least a PASI 35 would be considered cost-effective by conventional standards if it does not exceed $33 600 in cost.


Keywords: psoriasis, cost-utility analysis, health economics

Download Article [PDF] 

Readers of this article also read:

Paclitaxel attenuates renal interstitial fibroblast activation and interstitial fibrosis by inhibiting STAT3 signaling

Zhang L, Xu X, Yang R, Chen J, Wang S, Yang JQ, Xiang X, He Z, Zhao Y, Dong Z, Zhang D

Drug Design, Development and Therapy 2015, 9:2139-2148

Published Date: 15 April 2015

In vitro cytotoxicity of the ternary PAMAM G3–pyridoxal–biotin bioconjugate

Uram Ł, Szuster M, Gargasz K, Filipowicz A, Wałajtys-Rode E, Wołowiec S

International Journal of Nanomedicine 2013, 8:4707-4720

Published Date: 11 December 2013

Clinical studies with oral lipid based formulations of poorly soluble compounds

Dimitrios G Fatouros, Ditte M Karpf, Flemming S Nielsen, Anette Mullertz

Therapeutics and Clinical Risk Management 2007, 3:591-604

Published Date: 15 September 2007

Bortezomib (Velcade™) in the treatment of multiple myeloma

Antonia Field-Smith, Gareth J Morgan, Faith E Davies

Therapeutics and Clinical Risk Management 2006, 2:271-279

Published Date: 15 September 2006